Small Intestinal Bacterial Overgrowth Is Associated with Non- Alcoholic Fatty Liver Diseas

18 Apr 2016 Andrea Fialho, Andre Fialho, Prashanthi ota, Arthur J. McCullough, Bo Shen

Patients with SIBO have an increased risk for hepatic steatosis and may bene t from aggressive control of the risk factors for NAFLD including metabolic syndrome.

Cross-section study
6 effects
372 subjects

Reported Outcomes

DeterminantsOutcomeDetails

Small intestinal bacterial overgrowth (SIBO) Digestive outcome
Small intestinal bact...
Digestive system

Blood Pressure - Hypertension Cardiovascular outcome
Minor increase risk of Blood Pressure - Hype...
Cardiovascular system

Moderate evidence
35.4%

Small intestinal bacterial overgrowth (SIBO) Digestive outcome
Small intestinal bact...
Digestive system

Metabolic Syndrome Lymphatic outcome
Minor increase risk of Metabolic Syndrome
Lymphatic system

Moderate evidence
29.5%

Small intestinal bacterial overgrowth (SIBO) Digestive outcome
Small intestinal bact...
Digestive system

Type 2 Diabetes Lymphatic outcome
Minor increase risk of Type 2 Diabetes
Lymphatic system

Moderate evidence
68.9%

Small intestinal bacterial overgrowth (SIBO) Digestive outcome
Small intestinal bact...
Digestive system

Non Fatty Liver Disease Digestive outcome
Increased risk of Non Fatty Liver Disease
Digestive system

Moderate evidence
163.0%

Type 2 Diabetes Lymphatic outcome
Type 2 Diabetes
Lymphatic system

Non Fatty Liver Disease Digestive outcome
Increased risk of Non Fatty Liver Disease
Digestive system

Moderate evidence
204.0%

Obesity Musculoskeletal outcome
Obesity
Musculoskeletal system

Non Fatty Liver Disease Digestive outcome
Increased risk of Non Fatty Liver Disease
Digestive system

Moderate evidence
258.0%